A Phase 2/3 interventional study of Pirfenidone Capsules (400 mg) and Pirfenidone Capsules(600mg) in Radiation-induced Lung Injury and Immune-related Pneumonia, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Recruiting at 36 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Lung Injury with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Lung Injury · China.
Among the 22 studies in Lung Injury with a site in China, this one is the 4th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 6 of the 10 other live ones, and was the 20th registered.
114 studies on the registry are indexed under Lung Injury; 33 are open to participants now.
Browse Lung Injury studies →10 of the 22 studies in Lung Injury with a site in China are open now. Recruiting first, the newest first:
ChromX Health · Sites in China
Ages 18–100 · Healthy volunteers
Mao Enting · Sites in China
Ages 18–75
Sichuan University · Sites in China
Ages 18–75
Cell Energy Life Sciences Group Co. LTD · Sites in China
Ages 18–90
Fujian Medical University Union Hospital · Sites in China
Ages 60–100
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 25 Lung Injury studies recruiting now, 12 (48%) set no upper age limit and 8 (32%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 1 · Phase 4 1
First in 2011; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 298 is above the median of 62 across 75 interventional studies indexed under Lung Injury.
Median enrollment 100 across the 18 interventional studies, 5,026 across the 4 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing Continent Pharmaceutical Co, Ltd., one of the names counted as GNI Group Ltd.. Under that name alone:
Beijing Continent Pharmaceutical Co, Ltd. is the lead sponsor of 26 studies on the registry; 7 are open to participants now.
GNI Group Ltd. has 2 studies filed under Lung Injury — fewer than ten, so there is no comparison to draw.
3 of the studies in Lung Injury with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07388680Phase 3Beijing Continent Pharmaceutical Co, Ltd.Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia | 2026-12-30 |
| NCT06528418ChromX HealthIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath | 2026-12-30 |
| NCT06548802Tianjin Medical University General HospitalEfficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Lung Injury with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Radiation-induced lung injury (RILI) is one of the most common thoracic-radiotherapy complications, with an incidence as high as 31.4 %. Multiple studies have shown that RILI can adversely affect patient prognosis by disrupting treatment schedules. Moreover, the widespread clinical use of immune-checkpoint inhibitors (ICIs) has further increased pulmonary toxicity when radiotherapy (RT) is combined with ICIs. Checkpoint-inhibitor-related pneumonitis (CIP)-i.e., immune-mediated lung injury-may necessitate permanent discontinuation of ICIs, diminish survival benefit, and, in severe cases, directly threaten life. The diagnosis of both RILI and CIP is based on an integrated assessment of subjective symptoms and imaging findings.RILI typically occurs 1-3 months after completion of radiotherapy, whereas CIP may emerge at any point during treatment. The two entities share similar clinical presentations: fever, dry cough, chest tightness, dyspnoea, and pleuritic chest pain. Computed tomography (CT) is the most sensitive imaging modality. Pulmonary-function testing is another routinely used clinical metric; vital capacity, total lung capacity, forced expiratory volume in 1 s (FEV₁), and diffusing capacity of the lung for carbon monoxide (DLCO) may all decline, with DLCO being the most sensitive parameter. In advanced cases, arterial oxygen and carbon-dioxide tensions may also deteriorate.Currently, RILI is managed empirically with systemic corticosteroids and supportive care; however, this approach yields limited improvement in diffusing capacity or ventilatory function, and its ability to prevent radiation-induced pulmonary fibrosis (RPF) remains undefined. Corticosteroids also remain the mainstay of CIP therapy. Pirfenidone, a potent cytokine inhibitor, attenuates fibroblast activity by reducing production of transforming growth factor-β1 (TGF-β1), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF), thereby suppressing fibroblast proliferation and extracellular-matrix collagen synthesis. Pre-clinical efficacy studies have demonstrated robust anti-inflammatory, anti-oxidant, and anti-fibrotic effects in the lung.Because RILI and pneumonitis arising from combined radio-immunotherapy are often indistinguishable in clinical practice, and because both share pathogenetic features with idiopathic pulmonary fibrosis (IPF), the investigators initiated this phase II/III trial to address the unmet medical need for effective therapy. Building on prior pre-clinical and clinical data, the study aims to establish the optimal dose of pirfenidone capsules for RILI with or without concomitant CIP and to confirm efficacy and safety.Phase II (dose-finding): The study consists of a screening period (Day -28 to Day -1), a 168-day treatment-observation period (Day 1-Day 168), a safety follow-up (28 ± 7 days after the last dose), and subsequent disease-progression and survival follow-up. Ninety subjects with RILI, with or without CIP, who meet all eligibility criteria will be randomly assigned 1:1:1 to low-dose pirfenidone (400 mg TID), high-dose pirfenidone (600 mg TID), or matching placebo.Phase III (confirmatory): The dose of pirfenidone capsules for phase III will be determined jointly by the sponsor and investigators based on accumulated efficacy and safety data. The trial structure mirrors phase II: screening (Day -28 to Day -1), 168-day treatment-observation (Day 1-Day 168), safety follow-up (28 ± 7 days after the last dose), and disease-progression and survival follow-up. Eligible subjects with RILI ± CIP will be randomized 1:1 to receive either pirfenidone capsules (400 mg or 600 mg TID, taken with meals) or identical placebo. After completion of the 28-day post-treatment follow-up, all phase III participants will enter an extension phase for long-term survival assessment every 3 months (± 7 days).This trial will investigate the progression-free survival (PFS) and overall survival (OS) associated with pirfenidone capsules in patients with Grade 2 and 3 radiation-induced lung injury (RILI), with or without chemotherapy-induced pneumonitis (CIP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The functional level of major organs meets the following standards:
Biochemical examination: Total (TBIL), blood urea nitrogen (BUN), and creatinine (Cr) ≤ 1.5 value (ULN), or rate ≥ 50 mL/min; (ALT) or aspartate aminotransferase (AST) ≤ 2.0 ULN.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pirfenidone Capsules (Low-dose group: 400 mg, TID)
Drug: Pirfenidone Capsules (400 mg)
Pirfenidone Capsules (High-dose group: 600 mg, TID)
Drug: Pirfenidone Capsules(600mg)
Pirfenidone Capsules(0mg,TID)
Drug: Pirfenidone Capsules(0mg)
Low-dose group:400 mg, TID
Pirfenidone Capsules(600mg,TID)
Placebo(0mg,TID)
Phase II and Phase III: The absolute value of the change in the predicted percentage of lung carbon monoxide diffusion capacity (DLCO% predicted) from the baseline at week 24.
DLCO% is a core indicator for evaluating pulmonary gas exchange function, reflecting the efficiency of oxygen transfer from the alveoli into the bloodstream. It is crucial for the diagnosis and prognosis of interstitial lung disease, pulmonary vascular disease, and similar conditions. DLCO% = measured diffusing capacity of the lung for carbon monoxide ÷ predicted value × 100%. Absolute value change refers to the direct difference between two consecutive measurements (for example, a decrease from 65% to 55% represents an absolute value change of -10%).
Time frame: At the 24th week of the experiment
Phase II and Phase III: The absolute values of the changes in DLCO% at weeks 2, 4, 8, and 16 compared to the baseline.
Time frame: At weeks 2, 4, 8 and 16 of the trial
Phase II and III: Compared with the baseline, the changes in the measured values of pulmonary carbon monoxide diffusion capacity (DLCO) (in units of liters [L]) at weeks 2, 4, 8, 16, and 24.
Time frame: At weeks 2, 4, 8,16 and 24 of the trial
Phase II and Phase III: Changes in forced vital capacity (FVC) (in liters) from baseline at weeks 2, 4, 8, 16, and 24.
Time frame: At weeks 2, 4, 8,16 and 24 of the trial
Phase II and Phase III: The absolute value changes of forced vital capacity as a percentage of the predicted value (FVC%) from baseline at weeks 2, 4, 8, 16, and 24.
Time frame: At weeks 2, 4, 8,16 and 24 of the trial
Phase II and Phase III: Changes in forced expiratory volume in one second (FEV1) (in liters) from baseline at weeks 2, 4, 8, 16, and 24.
Time frame: At weeks 2, 4, 8,16 and 24 of the trial
Phase II and Phase III: The absolute value of the change in forced expiratory volume in one second as a percentage of the predicted value (FEV1%) from baseline at weeks 2, 4, 8, 16, and 24.
Time frame: At weeks 2, 4, 8,16 and 24 of the trial
Phase II and Phase III: Changes in FEV1/FVC from baseline at weeks 2, 4, 8, 16, and 24.
Time frame: At weeks 2, 4, 8,16 and 24 of the trial
Phase II and Phase III: Changes in the St. George's Respiratory Questionnaire (SGRQ) scores from baseline at weeks 4, 8, 16, and 24.
The St. George's Respiratory Questionnaire (SGRQ) score is the standard instrument for assessing health-related quality of life in patients with chronic airway diseases. It comprises 76 items grouped into three domains-symptoms, activity, and disease impact. Each domain score and the overall total score are scaled from 0 to 100: 0 denotes "complete absence of symptoms or limitation," whereas 100 indicates "maximal severity." Higher scores signify a greater adverse effect of the disease on daily life.
Time frame: At weeks 4, 8,16 and 24 of the trial
Phase II and Phase III: Changes in cough score from baseline at weeks 2, 4, 8, 16, and 24.
The cough score is a subjective instrument that quantifies the frequency, intensity, and disruptive impact of cough on daily activities and sleep into a 0-10-point or 0-100-mm scale; zero denotes complete absence of cough, and higher values indicate increasing symptom severity.
Time frame: At weeks 2, 4, 8,16 and 24 of the trial
Phase II and Phase III: Changes in the Modified Medical Research Council Dyspnea Scale (mMRC) score at weeks 2, 4, 8, 16, and 24 compared to the baseline.
The Modified Medical Research Council Dyspnea Scale (mMRC) is a five-level instrument that rapidly quantifies the extent to which breathlessness limits physical activity; higher grades indicate greater disability.
Time frame: At weeks 2, 4, 8,16 and 24 of the trial
Phase II and Phase III: Compared with the baseline, the changes in computed tomography (CT) imaging scores at weeks 4, 8, 16, and 24
CT imaging score is a standardized method that converts anatomical or functional features observed on CT scans into quantifiable numerical values, used for disease diagnosis, staging, treatment response monitoring, or prognostic assessment.Referring to the HRCT scoring system, the scores were assigned by imaging experts after consensus , with higher values generally indicating more severe disease.
Time frame: At weeks 4, 8,16 and 24 of the trial
Phase II and Phase III: The proportion of subjects with CIP at baseline who discontinued immunotherapy and experienced immune reactivation during the study period.
Time frame: Within 24 weeks
Phase II and Phase III: The proportion of subjects whose lung injury grade decreased by at least one level compared to the baseline at week 24.
According to the Common Terminology Criteria for Adverse Events, Version 5.0, pulmonary injury is graded, with higher grades indicating more severe symptoms.
Time frame: Within 24 weeks
Phase II and Phase III: The proportion of subjects achieving a lung injury level of ≤ 1 at the 24th week compared to the baseline.
According to the Common Terminology Criteria for Adverse Events, Version 5.0, pulmonary injury is graded, with higher grades indicating more severe symptoms.
Time frame: Within 24 weeks
Phase II and Phase III: The time required for the subjects to first achieve a lung injury level of ≤ 1.
According to the Common Terminology Criteria for Adverse Events, Version 5.0, pulmonary injury is graded, with higher grades indicating more severe symptoms.
Time frame: Within 24 weeks
Phase II and Phase III: The proportion of subjects who experienced their first acute pulmonary deterioration or died for any reason within 24 weeks of treatment.
Acute pulmonary deterioration is defined as the unexplained worsening or new onset of cough, dyspnea, hypoxia, or pneumonia from the completion of initial treatment up to Week 24, persisting for \>4 days, with chest CT showing new or increased diffuse pulmonary infiltrates in the absence of pneumothorax or pleural effusion, and after exclusion of pneumonia, congestive heart failure, pulmonary embolism, or cancer progression. Pulmonary deterioration occurring within the first 2 weeks after initial treatment is not counted toward the endpoint, allowing full resolution of initial symptoms.
Time frame: Within 24 weeks
Phase II and Phase III: Analyze the blood drug concentration of pirfenidone capsules, evaluate the steady-state blood drug trough concentration for individual patients and each group of people at specific treatment time poin
Time frame: on days 1, 14, 28, 56, 112, and 168 of the trial
Phase II and Phase III: Analyze the blood drug concentration of pirfenidone capsules, evaluate the PopPK characteristics for individual patients and each group of people at specific treatment time poin
Time frame: on days 1, 14, 28, 56, 112, and 168 of the trial
Phase II and Phase III: Adverse events/serious adverse events (AE/SAE).
Adverse Event (AE) refers to any untoward and unintended medical occurrence experienced by a trial participant during treatment or clinical investigation, regardless of causal relationship to the investigational product. Serious Adverse Event (SAE) is a subset of AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, causes persistent or significant disability/incapacity, leads to congenital anomaly/birth defect, or is judged medically important by the investigator. According to the Common Terminology Criteria for Adverse Events, Version 5.0, pulmonary injury is graded, with higher grades indicating more severe symptoms.
Time frame: Within 24 weeks
Phase II and Phase III:Number of participants with abnormal ECG readings
Time frame: At weeks 2, 4, 8,16 and 24 of the trial
Phase II and Phase III: vital signs( blood pressure).
Record patient's systolic and diastolic blood pressure
Time frame: At weeks 2, 4, 8,16 and 24 of the trial
Phase II and Phase III: vital signs(pulse rate).
Time frame: At weeks 2, 4, 8,16 and 24 of the trial
Phase II and Phase III: vital signs(body temperature).
Time frame: At weeks 2, 4, 8, 16 and 24 of the trial
Phase II and Phase III: vital signs( respiratory rate data).
Time frame: At weeks 2, 4, 8, 16 and 24 of the trial
Phase II and Phase III: laboratory tests(complete blood count).
Time frame: At weeks 2, 4, 8, 16 and 24 of the trial
Phase II and Phase III: Number of participants with abnormal urinalysis
Time frame: At weeks 2, 4, 8, 16 and 24 of the trial
Phase II and Phase III: Number of participants with abnormal laboratory tests results (blood biochemistry)
Time frame: At weeks 2, 4, 8, 16 and 24 of the trial
Phase II and Phase III: Number of participants with abnormal laboratory tests results (coagulation function)
Time frame: At weeks 2, 4, 8, 16 and 24 of the trial
Phase II and Phase III: laboratory tests( pregnancy test for safety assessment).
Time frame: At weeks 2, 4, 8, 16 and 24 of the trial
Phase II and Phase III : Analysis of the correlation between cytokines and efficacy and safety.
Flow cytometry was employed to analyze the correlation between pirfenidone and immune-cell subsets (CD8⁺ T cells, CD4⁺ T cells, regulatory T cells \[Treg\], and macrophages).
Time frame: on days 1, 28, and 168 of the trial
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Continent Pharmaceutical Co, Ltd. →